JAK inhibitor ( DrugBank: - )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
46	悪性関節リウマチ	5
50	皮膚筋炎／多発性筋炎	1

46. 悪性関節リウマチ

臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05451615 (ClinicalTrials.gov)	September 30, 2022	17/6/2022	Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis	Clinical Efficacy and Safety of Real-world Patients With Refractory Rheumatoid Arthritis (D2TRA) Receiving Abatacept in Combination With a Janus Kinase (JAK) Inhibitor	Abatacept;Treatment Compliance;Rheumatoid Arthritis	Drug: Janus Kinase Inhibitor;Drug: Abatacept	Zhejiang Provincial People's Hospital	NULL	Recruiting	N/A	N/A	All	90	Phase 3	China
2	NCT05379322 (ClinicalTrials.gov)	July 2022	12/5/2022	The Use of Synovial Biopsies in Predicting Response to Biologic Therapy in Rheumatoid Arthritis Patients	The Use of Synovial Biopsies in Predicting Response to Biologic Therapy in Rheumatoid Arthritis Patients	Rheumatoid Arthritis	Drug: Anti-TNF;Drug: JAK inhibitor	Abu Dhabi Stem Cells Center	NULL	Withdrawn	18 Years	N/A	All	0	Phase 3	United Arab Emirates
3	ChiCTR2100048699	2021-05-25	2021-07-12	A multicentre, randomized, parallel-controlled clinical study of the efficacy and safety of Iguratimod combination therapy with JAK inhibitor in the treatment of csDMARDs-IR active rheumatoid arthritis	Clinical cohort study of organ injury and repair in severe rheumatic diseases---rheumatoid arthritis	Rheumatoid Arthritis	A:Iguratimod combination therapy with JAK inhibitor;B:JAK inhibitor;	Qilu Hospital of Shandong University	NULL	Recruiting	18	65	Both	A:180;B:180;		China
4	NCT05090410 (ClinicalTrials.gov)	March 3, 2021	30/9/2021	Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate	Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate: Comparative Study With Filgotinib and Tocilizumab Examined by Clinical Index as Well as Musculoskeletal Ultrasound Assessment	Rheumatoid Arthritis;JAK Inhibitor;IL-6 Inhibitor;Musculoskeletal Ultrasound;Biomarker	Drug: filgotinib 200mg/day;Drug: subcutaneous tocilizumab 162mg/biweekly	Atsushi Kawakami	Gilead Sciences	Recruiting	20 Years	N/A	All	400	Phase 3	Japan
5	NCT04378621 (ClinicalTrials.gov)	October 1, 2020	8/4/2020	Effect of Antiinflammatory Treatment Versus Hand Training on Neuropsychiatric Comorbidity in RA-patients	Treatment of Inflammation Versus Hand Training to Prevent and Revert Neuropsychiatric Comorbidity in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis;Pain;Fatigue;Cognitive Decline;Depression;Brain Diseases;Hand Rheumatism	Drug: TNF-a inhibitor OR JAK inhibitor;Other: Hand training	Vastra Gotaland Region	NULL	Active, not recruiting	45 Years	75 Years	All	212	N/A	Sweden

50. 皮膚筋炎／多発性筋炎

臨床試験数 : 194 / 薬物数 : 244 - (DrugBank : 89) / 標的遺伝子数 : 50 - 標的パスウェイ数 : 151

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04966884 (ClinicalTrials.gov)	April 2, 2020	15/7/2021	The Efficacy and Safety of JAK Inhibitor in the Treatment of Anti-MDA5 Antibody-positive Dermatomyositis Patients	The Efficacy and Safety of JAK Inhibitor in the Treatment of Anti-MDA5 Antibody-positive Dermatomyositis Patients	Dermatomyositis, Adult Type	Drug: JAK Inhibitor	First Affiliated Hospital Xi'an Jiaotong University	NULL	Recruiting	18 Years	70 Years	All	20	Phase 4	China